Jeff Wyzykowski is a patent agent in the life sciences practice group and a member of Cooley's litigation department. He joined Cooley in 2005 and is resident in the Washington, DC office. Jeff specializes in patent counseling issues including due diligence, patentability and freedom to operate opinions.
Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its $147.9 million initial public offering.
Blue Owl Capital Invests up to $1.05 Billion in BridgeBio Pharma
January 17, 2024
Cooley advised Blue Owl Capital, a top asset manager redefining alternatives, on its strategic investment a $300 million royalty financing and a $450 million credit facility in BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers.
Cooley advised global investment firm Sixth Street on its strategic investment in Blueprint Medicines, a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Lawyers Mischi a Marca, Matt Browne, Matt Scarano, Addison Pierce, Matt Kong and Nick Neuteufel led the Cooley team advising Sixth Street.
Cooley advised Forbius – a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases – on its agreement to sell to Bristol Myers Squibb. Barbara Borden, Marya Postner and Rowook Park led the Cooley team advising Forbius.